Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

The following tables present financial information by segment:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
Net revenue:
Products & Healthcare Services	$	2,034,279	$	1,943,467	$	6,019,721	$	5,789,679
Patient Direct		686,846		648,275		1,985,089		1,888,138
Consolidated net revenue	$	2,721,125	$	2,591,742	$	8,004,810	$	7,677,817
Operating income:
Products & Healthcare Services	$	4,233	$	19,803	$	27,187	$	24,564
Patient Direct		79,932		64,435		190,598		169,349
Acquisition-related charges and intangible amortization		(21,097)		(30,217)		(61,395)		(74,609)
Exit and realignment charges, net		(28,880)		(30,180)		(85,530)		(74,817)
Litigation and related charges(1)		(9,984)		—		(16,662)		—
Consolidated operating income	$	24,204	$	23,841	$	54,198	$	44,487
Depreciation and amortization:
Products & Healthcare Services	$	18,382	$	20,021	$	60,832	$	57,360
Patient Direct		43,232		53,631		138,756		159,280
Consolidated depreciation and amortization	$	61,614	$	73,652	$	199,588	$	216,640
Share-based compensation:
Products & Healthcare Services	$	4,141	$	2,917	$	13,696	$	10,649
Patient Direct		1,198		1,699		4,131		5,113
Other(2)		341		1,126		1,454		1,655
Consolidated share-based compensation	$	5,680	$	5,742	$	19,281	$	17,417
Capital expenditures:
Products & Healthcare Services	$	17,763	$	5,023	$	29,130	$	17,957
Patient Direct		43,755		45,565		127,596		133,610
Consolidated capital expenditures	$	61,518	$	50,588	$	156,726	$	151,567

⁽¹⁾ Litigation and related charges includes settlement costs and related fees of legal matters within our Apria division, which do not occur in the ordinary course of our business, are non-recurring/infrequent and are inherently

unpredictable in timing and amount. These charges are reported within Other operating expense, net in our Statements of Operations for the three and nine months ended September 30, 2024.

⁽²⁾ Other share-based compensation expense is captured within Exit and realignment charges, net or Acquisition-related charges for the three and nine months ended September 30, 2024 and 2023.

Schedule of Consolidated Total Assets

	September 30, 2024		December 31, 2023
Total assets:
Products & Healthcare Services	$	2,519,690	$	2,359,825
Patient Direct		2,516,138		2,490,460
Segment assets		5,035,828		4,850,285
Cash and cash equivalents		45,454		243,037
Consolidated total assets	$	5,081,282	$	5,093,322

Schedule of Financial Information by Geographic Area

The following table presents net revenue by geographic area, which were attributed based on the location from which we ship products or provide services:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
Net revenue:
United States	$	2,661,469	$	2,518,952	$	7,821,088	$	7,470,424
International		59,656		72,790		183,722		207,393
Consolidated net revenue	$	2,721,125	$	2,591,742	$	8,004,810	$	7,677,817